Clinical Trial Update: Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A phase 2 study of cediranib maleate in adults with relapsed/refractory or untreated acute myeloid leukemia or high-risk myelodysplastic syndromes has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 2 | Status: COMPLETED | Results posted: 2013-07-10